Summary of Nano-X Imaging Conference Call (December 10, 2025) Company Overview - **Company**: Nano-X Imaging (Ticker: NNOX) - **Industry**: Medical Imaging Technology - **Core Offering**: Advanced diagnostic imaging solutions, including hardware, AI solutions, teleradiology services, and OEM business [2][3][4] Key Points and Arguments Business Model and Technology - **Nano-X Arc**: A digital multi-source 3D tomosynthesis imaging system cleared by the FDA and CE, ready for commercialization in the U.S. and European markets [2][3] - **AI Solutions**: Comprises three main applications for chest, bone, and liver diagnostics, all FDA and CE cleared, aimed at early detection of chronic diseases [3][21] - **Teleradiology Services**: Acquired USARAD in November 2021, enhancing service offerings [3] - **OEM Business**: Involves proprietary tube and chip technology, applicable in medical and other industries [4][23] Recent Developments - **FDA Clearance**: Recently cleared the Arc-X, a second-generation imaging device that is smaller, mobile, and has lower radiation exposure compared to traditional CT machines [11][12] - **Commercial Deployment**: Started commercial deployment of Arc systems in the U.S. and EU, with consistent utilization and clinical adoption reported [6][14] - **Production Plans**: Initial production of Nanox.ARC-X in Israel, with mass production set to commence in Thailand in 2026 [14] Financial Highlights - **Q3 2025 Financials**: - Cash and cash equivalents: $55 million - Shareholders' equity: $156 million - Revenue: $3.5 million - Inventory for pay-per-use model: $49.5 million [24][25] - **Funding**: Recently raised $50 million to support commercialization efforts [24][27] Market Strategy - **Target Markets**: Imaging centers, orthopedic clinics, multispecialty clinics, and urgent care facilities [14] - **Reimbursement Model**: Utilizes CPT code 76100, allowing operators to charge $90-$110 per scan, with a pay-per-use model at $30 per scan [13][17] - **Sales Strategy**: Direct sales force in the U.S. and distributor sales in Europe, focusing on shorter sales cycles due to lower capital investment required [15][17] Clinical and Competitive Advantages - **3D Imaging**: Provides superior imaging capabilities compared to traditional 2D and CT imaging, with reduced radiation exposure [18][19] - **AI Integration**: AI tools enhance diagnostic capabilities and integrate with PACS systems, providing value to radiologists and other medical professionals [21][22] Future Outlook - **Focus on Profitability**: Transitioning from R&D to a product-focused company, with an emphasis on commercialization and shareholder value [27][28] - **AI Expansion**: Plans to accelerate monetization of AI tools and expand business models, indicating potential growth in 2026 [29][30] Additional Important Information - **Regulatory Approvals**: Holds multiple regulatory approvals, including FDA and CE, with installations in Israel and Ghana for clinical data accumulation [18] - **Market Reception**: Positive reception at the RSNA conference, indicating strong interest from prospective clients and distributors [26]

Core Insights - Crude Value Insights provides an investment service and community focused on the oil and natural gas sector, emphasizing cash flow and the companies that generate it, which leads to value and growth prospects with real potential [1] Group 1 - The service includes access to a 50+ stock model account, in-depth cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [1] - Subscribers are offered a two-week free trial to explore the services related to oil and gas investments [2]

Group 1 - Nano-X Imaging reported positive news with a distribution agreement in France, leading to a share price increase of over 9% [1] - The agreement with Althea France allows for the introduction and sale of the Nanox.ARC 3D imaging system in the French market, which is now certified for sale in the EU [2][3] - The CEO emphasized the strategic importance of France and highlighted Althea's expertise in imaging technology as a valuable partnership for growth [3] Group 2 - Nano-X is expanding its European presence, having previously signed similar distribution agreements in the Czech Republic, Greece, and Romania [3][4] - The company's products are positioned as cost-effective alternatives, appealing to healthcare providers with limited budgets [4] - While the impact of the Althea France deal on Nano-X's fundamentals is unclear, it is generally viewed as a positive development [4]

Core Insights - Nanox Imaging Ltd has entered into a distribution agreement with Althea France to introduce its CE-marked Nanox.ARC system in the French healthcare sector, marking its fourth distribution agreement in Europe [1][2][3] Company Overview - Nanox is focused on advancing medical imaging technology, aiming to drive the transition to preventive healthcare through affordable solutions that leverage AI and proprietary digital X-ray sources [4][5] Partnership Details - Althea France will manage the market introduction, sales, and service of the Nanox.ARC, which is a multi-source digital tomosynthesis system designed to enhance diagnostic capabilities at a lower cost compared to traditional systems [2][3] - The partnership is expected to leverage Althea's established relationships with hospitals and clinics across France, facilitating the introduction of Nanox's imaging platform [3] Market Strategy - France is identified as a strategic market for Nanox, with the partnership expected to expand access to high-quality, affordable imaging services for patients [3] - The collaboration follows previous agreements in Greece, Romania, and the Czech Republic, indicating a growing presence in the European market [1][2]

Core Insights - Nanox's AI solutions, HealthOST and HealthVCF, have been recommended for use in UK NHS hospitals for three years as part of an evaluation of AI in bone disease detection [1][2][3] - The National Institute for Health and Care Excellence (NICE) has included these solutions in an Early Value Assessment to gather evidence on their effectiveness in detecting vertebral fragility fractures [2][3] - The AI technologies aim to enhance the detection of vertebral fragility fractures through opportunistic detection in X-ray images and CT scans [3] Company Overview - Nanox.AI is a subsidiary of Nanox focused on deep-learning medical imaging analytics, targeting chronic and acute diseases [6] - The company aims to drive the transition to preventive healthcare by providing affordable medical imaging technologies [7] - Nanox's ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all designed to improve early detection and treatment [8] Product Details - HealthOST and HealthVCF utilize existing CT scans to support early detection of bone diseases without additional imaging or radiation exposure [4] - These solutions are integrated with existing PACS workflows, allowing real-time identification of clinically significant findings [5] - The tools are expected to improve patient outcomes by enabling timely preventive interventions for conditions like osteoporosis [5]

Core Viewpoint - Nanox Imaging Ltd has announced a registered direct offering of 3,826,530 ordinary shares, expected to generate approximately $15 million in gross proceeds, aimed at strengthening its balance sheet and supporting growth initiatives [1][3]. Group 1: Offering Details - The offering involves the sale of 3,826,530 ordinary shares to a single institutional investor, with gross proceeds anticipated to be around $15 million before expenses [1]. - The closing of the offering is expected on or about November 25, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and general corporate purposes [2]. Group 3: Company Growth Strategy - The CEO of Nanox stated that the capital raise will enhance the company's balance sheet and accelerate key growth initiatives, including technology advancement, market expansion, and AI infrastructure enhancement [3]. - The company aims to make high-quality medical imaging more accessible globally as it scales deployments and expands capabilities [3]. Group 4: Company Overview - Nanox is focused on transitioning to preventive healthcare through affordable medical imaging technologies, leveraging advanced AI and proprietary digital X-ray sources [6]. - The company's ecosystem includes various components such as Nanox.ARC, Nanox.AI, Nanox.CLOUD, and Nanox.MARKETPLACE, all aimed at improving early detection and treatment in healthcare [7].

Core Insights - Nano-X Imaging experienced a significant stock market surge, increasing by over 26% following the release of its quarterly earnings report [1] Financial Performance - The company reported third-quarter revenue of $3.45 million, marking a 13% year-over-year increase [2] - The net loss deepened to $9.9 million ($0.15 per share), compared to a loss of $8.7 million in the previous year [2] - Despite the increased loss, it was better than analysts' expectations, who had predicted a loss of $0.19 per share [3] - Nano-X narrowly missed revenue expectations, with analysts forecasting $3.5 million [3] Future Outlook - The company did not provide full-year financial guidance but projected revenue of $35 million for the next year, which would be more than three times the total for 2024 [4] - Recent developments include the acquisition of Vaso Healthcare IT and entry into the European market through two distribution deals, which are expected to support future growth [6] Market Reaction - The stock's performance on Friday was seen as possibly overly enthusiastic, but the company is perceived to be moving in the right direction [7]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [35] - Revenue from AI solutions for the reported period was $0.1 million, with a gross loss of $1.9 million [35] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][15] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [7] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, reinforcing its position in the medical AI sector, and deepening its foothold in the U.S. healthcare system [4][5] - The acquisition of VasoHealthcare IT is intended to enhance customer service and expand the company's operational capabilities [10][22] - The company is preparing to launch the next-generation Nanox.ARC X system, which is designed to meet diverse clinical needs and expand the addressable market [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [5][39] - The company anticipates that the AI business segment will achieve EBITDA break-even on a quarterly basis in 2026, while the overall company aims for break-even in 2027 [30][62] Other Important Information - The company has a strong presence planned at the RSNA annual meeting, where it will provide insights into its commercial progress and future strategy [13][21] - The company is actively engaged in clinical trials to support the use of its solutions in lung cancer detection and management [18][20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The CEO mentioned that a few dozen systems were deployed, with some pending installation and regulatory approvals [44] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The CFO indicated that the majority of agreements are expected to be MSES, with some CapEx sales anticipated [48] Question: Could you talk about how OpEx could look over the next four to six quarters? - Management indicated that sales and marketing expenses will increase due to deployment efforts, while R&D expenses will be more controlled [56] Question: Could you talk about Vaso and the types of customers they currently have? - The CEO stated that Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities [58] Question: Could you reiterate the break-even expectations for the AI business and ARC division? - Management reiterated that the AI business is expected to reach quarterly break-even in 2026, while the ARC division aims for break-even in 2027 [60][62]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [32] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [32] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [33] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [34] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for Q3 2025, with a gross loss of $1.7 million [35] - Revenue from AI solutions for Q3 2025 was $0.1 million, with a gross loss of $1.9 million, compared to revenue of $0.4 million and a gross loss of $1.6 million in the comparable period [35] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][14] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [7] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, increasing revenues, and accelerating its path to profitability [4] - The strategy includes reinforcing its position in the medical AI sector and deepening its foothold in the U.S. healthcare system [4] - The acquisition of VasoHealthcare IT is intended to enhance the company's AI capabilities and customer service [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by current business trajectory and new partnerships [5][30] - The company anticipates that the AI business segment will achieve EBITDA break-even on a quarterly basis in 2026, while the overall company expects to reach EBITDA break-even in 2027 [31] Other Important Information - The company is preparing to launch its next-generation platform, the Nano-X ARC X system, which is designed to meet diverse customer needs and expand the addressable market [8] - The company has entered into a multi-year volume supply agreement with Fabrinet to support scalable manufacturing of Nano-X ARC systems [30] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The revenue was generated from a combination of scans and OEM services, with a few dozen systems actively scanning [43][45] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The majority of agreements are expected to be MSES, with some CapEx sales anticipated [47][48] Question: Could you talk about how OpEx could look over the next four to six quarters? - Investment in deployment efforts will increase, while R&D expenses are expected to be more controlled as focus shifts to commercialization [56] Question: Could you talk about Vaso and the types of customers they currently have? - Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities for Nano-X [58] Question: Could you reiterate the break-even targets for the AI business and ARC division? - The AI business is expected to reach quarterly break-even in 2026, while the ARC division aims for break-even in 2027 [61][63] Question: How should we think about the cadence of the $35 million revenue target for 2026? - Revenue is expected to start slowly in Q1 and ramp up over the quarters, achieving the target by Q4 [70]

Financial Data and Key Metrics Changes - The company reported a GAAP net loss of $13.7 million for Q3 2025, compared to a net loss of $13.6 million in Q3 2024 [31] - Revenue for Q3 2025 was $3.4 million, an increase from $3.0 million in the comparable period [31] - Non-GAAP gross loss for the reported period was $0.3 million, compared to a gross loss of $0.2 million in the comparable period, representing a gross loss margin of approximately 8% [32] Business Line Data and Key Metrics Changes - Revenue from teleradiology services for Q3 2025 was $3.1 million, with a gross profit of $0.1 million, compared to revenue of $2.6 million and a gross profit of $0.3 million in the comparable period [32] - Revenue from the sale and deployment of imaging systems and OEM services amounted to $175,000 for the reported period, with a gross loss of $1.7 million [34] - Revenue from AI solutions for Q3 2025 was $0.1 million, with a gross loss of $1.9 million, compared to revenue of $0.4 million and a gross loss of $1.6 million in the comparable period [34] Market Data and Key Metrics Changes - The company is expanding its presence in Europe with new agreements in the Czech Republic and France, indicating rising demand for its imaging ecosystem [7][16] - The company aims to deploy 100 systems worldwide by the end of 2025, with several systems pending regulatory approval [8] Company Strategy and Development Direction - The company is focused on building a comprehensive medical imaging portfolio, increasing revenues, and accelerating its path to profitability [5] - The strategy includes reinforcing its position in the medical AI sector and deepening its foothold in the U.S. healthcare system [5] - The acquisition of VasoHealthcare IT is intended to enhance the company's AI infrastructure and customer service capabilities [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over $35 million in revenues for 2026, driven by strategic partnerships and the acquisition of VasoHealthcare IT [6][38] - The company anticipates reaching EBITDA break-even on a quarterly basis in 2026 for the AI business segment and in 2027 for the overall company [30][44] Other Important Information - The company is preparing to launch its next-generation Nano-X ARC X system at the RSNA annual meeting, which is expected to enhance market penetration [9] - The company is actively engaged in clinical trials to validate the effectiveness of its imaging solutions, particularly in lung cancer detection [20] Q&A Session Summary Question: How many systems were in the field and performing scans that resulted in your revenue of $175,000? - The revenue was generated from a combination of scans and OEM services, with several systems being installed and awaiting regulatory approvals [40] Question: What types of agreements should we be thinking about in terms of those being lease versus capital sales? - The majority of agreements are expected to be MSES, with some CapEx sales anticipated [40] Question: Could you talk about how OpEx could look over the next four to six quarters? - Investment in deployment efforts, particularly sales and marketing expenses, is expected to increase, while R&D expenses may be tamed [42] Question: Could you talk about Vaso and the types of customers they currently have? - Vaso's customers are primarily medical-related, serving hospitals and imaging centers, presenting cross-selling opportunities for Nano-X [42] Question: Could you reiterate the break-even expectations for 2026 and 2027? - The AI business is expected to achieve quarterly break-even in 2026, while the ARC hardware business aims for break-even in 2027 [44][46]